Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Characteristics of HPV integration in cervical adenocarcinoma and squamous carcinoma. | J Cancer Res Clin Oncol | 2023 | 37966613 | PubTator, text mining | PubMed |
| AuCFSR: Authentication and Color Face Self-Recovery Using Novel 2D Hyperchaotic System and Deep Learning Models. | Sensors (Basel) | 2023 | 37960656 | PubTator, text mining | PubMed |
| Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. | Cancers (Basel) | 2023 | 37958398 | PubTator, text mining | PubMed |
| A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis. | Diagnostics (Basel) | 2023 | 37958189 | PubTator, text mining | PubMed |
| DNA damage repair mutations in pancreatic cancer- prognostic or predictive? | Front Oncol | 2023 | 37954082 | PubTator, text mining | PubMed |
| HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. | Cell Rep Med | 2023 | 37951219 | PubTator, text mining | PubMed |
| Most large structural variants in cancer genomes can be detected without long reads. | Nat Genet | 2023 | 37945902 | PubTator, text mining | PubMed |
| Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. | Oncogene | 2023 | 37945748 | PubTator, text mining | PubMed |
| Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. | Acta Neuropathol Commun | 2023 | 37932833 | PubTator, text mining | PubMed |
| Quantification of evolved DNA-editing enzymes at scale with DEQSeq. | Genome Biol | 2023 | 37932818 | PubTator, text mining | PubMed |
| Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. | Lancet Oncol | 2023 | 37922930 | PubTator, text mining | PubMed |
| Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. | ESMO Open | 2023 | 37922692 | PubTator, text mining | PubMed |
| Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers. | Int J Mol Sci | 2023 | 37894756 | PubTator, text mining | PubMed |
| De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? | Cancers (Basel) | 2023 | 37894312 | PubTator, text mining | PubMed |
| Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases. | Biomedicines | 2023 | 37893099 | PubTator, text mining | PubMed |
| FIGNL1 AAA+ ATPase remodels RAD51 and DMC1 filaments in pre-meiotic DNA replication and meiotic recombination. | Nat Commun | 2023 | 37891173 | PubTator, text mining | PubMed |
| Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors. | J Neurooncol | 2023 | 37878192 | PubTator, text mining | PubMed |
| Extracting Potential New Targets for Treatment of Adenoid Cystic Carcinoma using Bioinformatic Methods. | Iran Biomed J | 2023 | 37873683 | PubTator, text mining | PubMed |
| Mutational topography reflects clinical neuroblastoma heterogeneity. | Cell Genom | 2023 | 37868040 | PubTator, text mining | PubMed |
| Identification of a RAD51B enhancer variant for susceptibility and progression to glioma. | Cancer Cell Int | 2023 | 37858068 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=7